Fully Human Antibody / TCR Platforms

BsADC Platform

Bispecific ADCs targeting dual tumor-associated antigens (TAAs) enhance cancer treatment by overcoming drug resistance, improving tumor specificity, boosting internalization for better tumor killing, and ensuring stronger, longer-lasting effects in heterogeneous tumors.
  • 20+
    BsADC Assets
  • 200+
    TAA Antibody Backbones
Request Data Package Schedule a Meeting
related resource

on this page

  • Advantages of Biocytogen's BsADC Platform
  • Discovery of Novel BsADCs:
  • Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play

Webinars

View All

    Posters

    View All
      Advantages of Biocytogen's Novel bsADC Platform
      • RenLite-derived common light chain antibodies are easy to assemble into BsAb with low mismatch rate and ideal physiochemical properties.
      • Combined with target gene knockout strategy, RenLite KO mice can generate antibodies with increased diversity, potentially against novel epitopes and with cross-species reactivity.
      • Proprietary linker/payload system BLD1102
      • Rapid generation of high-quality BsAbs/BsADCs for high-throughput in vitro and in vivo screening
      Advantages of Biocytogen's Novel bsADC Platform
      Novel linker/payload system BLD1102 independently developed by Biocytogen

      Briefly, BLD1102 is a new ADC platform developed by Biocytogen independently.

      • BCPT02 is a novel topoisomerase 1 inhibitor with broad-spectrum and potent tumor killing ability.
      • The uniquely designed cleavable linker has excellent hydrophilicity, making ADCs as hydrophilic as monoclonal antibodies, greatly improving ADC's physiochemical properties.
      • BLD1102-ADCs exhibit good stability in plasma and more potent tumor killing compared to vcMMAE.
      • BLD1102 demonstrated good tolerabilities in preclinical non-human primates.
      Biocytogen's RenLite-based BsADC Platform

      BsADC developed from RenLite mice

      BsADC developed from RenLite mice
      Discovery of Novel BsADCs:

      As part of Biocytogen's Project Integrum, combinations of TAA-targeting antibodies generated from RenLite mice are subsequently assembled and evaluated in vivo for pharmacologic efficacy, and subjected to in vitro analyses. The company's large animal translational platform will further screen out products with better translational properties:

      Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play
      View More
      30+ BsADC Programs Available for Partnership
      Product Number Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      BCG017 PTK7 x EGFR
      		Preclinical
      BCG044 HER3 x EPCAM
      		Preclinical
      BCG040 B7-H4 x B7-H4
      		Preclinical
      BCG041 B7-H3 x MUC1
      		Preclinical
      BCG033 PTK7 x TROP2
      		Preclinical
      BCG023 FOLR1 x MUC1
      		Preclinical
      BCG025 DLL3 x B7-H3
      		Preclinical
      BCG030 DLL3 x SEZ6
      		Preclinical
      BCG016 TPBG x MUC1
      		Candidate Selection
      BCG039 TROP2 x NECTIN-4
      		Candidate Selection
      - CDH17 x MET
      		Candidate Selection
      - B7-H4 x EPCAM
      		Candidate Selection
      - B7-H4 x HER3
      		Candidate Selection
      - MUC1 x B7-H4
      		Candidate Selection
      - TROP2 x B7-H4
      		Candidate Selection
      - FOLR1 x FOLR1
      		Candidate Selection
      BCG026 FAP x GPC1
      		Candidate Selection
      BCG045 MUC1 x TROP2
      		Candidate Selection
      - MSLN x CDH3
      		Candidate Selection
      - MET x CDH3
      		Leads Selection
      - MET x EPCAM
      		Leads Selection
      - MET x B7-H3
      		Leads Selection
      - FAP x B7-H3
      		Leads Selection
      - CDH6 x FOLR1
      		Leads Selection
      - MUC16 x FOLR1
      		Leads Selection
      - EGFR x ITGB6
      		Leads Selection
      - CD142 x NECTIN-4
      		Leads Selection
      - MUC16 x FOLR1
      		Leads Selection
      - CDCP1 x B7-H3
      		Leads Selection
      - CDH3 x EGFR
      		Leads Selection
      - CLEC12A x CD33
      		Leads Selection
      10+ ADC Programs Available for Partnership
      Product Number Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      BCG014 CDH3
      		CMC
      BCG018 ITGB6
      		CMC
      BCG029 ADAM9
      		Candidate Selection
      BCG015 TM4SF5
      		Candidate Selection
      BCG037 PALP
      		Candidate Selection
      BCG047 FOLR1(nano)
      		Candidate Selection
      - DLL3(nano)
      		Candidate Selection
      - CLDN1
      		Candidate Selection
      - MSLN
      		Candidate Selection
      - HHLA2
      		Leads Selection
      BCG046 CDCP1
      		Leads Selection
      - EPHA5
      		Leads Selection
      - CLDN4
      		Leads Selection
      - CLDN3
      		Hits Selection